How the hell have they managed to make a VACCINE already when this virus is supposedly only a few months old???
Can you say FORCED DEADLY VACCINE COMING TO AN ARM NEAR YOU!!!!
Investor's Business Daily
TECHNOLOGY
Moderna Rockets After Dosing First Patient In Coronavirus Vaccine Test
ALLISON GATLIN0
4:58 PM ET 03/16/2020
Shares of MRNA stock rocketed Monday after the biotech company dosed the first patient in a study of its coronavirus vaccine.
Thanks for being here Scott glad to be here on today's podcast.
The drug aims to use a natural function called messenger RNA to protect against SARS-CoV-2, the name of the virus that causes Covid-19. Covid-19 is a new form of coronavirus discovered late last year in China. The Phase 1 study will test the coronavirus vaccine in 45 healthy adults.
Already, Moderna (MRNA) Chief Medical Officer Tal Zaks says the biotech company is planning for a Phase 2 study. The news sent MRNA stock soaring. On the stock market today, MRNA stock flew 24.4%, to 26.49. In after-hours action, shares added another 6.9% jump.
"This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2, and we expect it to provide important information about safety and immunogenicity (the ability to provoke an immune response in the body)," Zaks said in a written statement.
MRNA Stock Rockets On Coronavirus Vaccine
In total, it took Moderna and the National Institutes of Health — which is running the Phase 1 test — to discover, develop and administer the first dose of a coronavirus vaccine. Shares of MRNA stock have been volatile throughout the Covid-19 correction, however.
In the Phase 1 test, patients will receive two doses of Moderna's coronavirus vaccine 28 days apart. Patients will be followed through 12 months after the second vaccination. The study will evaluate the drug's safety and whether it can spark an immune response.
Meanwhile, Moderna said it's preparing to ask the Food and Drug Administration for permission to begin a Phase 2 study. Moderna would run this test itself. The potential midstage test could begin in a few months, the biotech company said.
Shares of MRNA stock have a strong Relative Strength Rating of 95 out of a best-possible 99. The RS Rating is a 1-99 measure of a stock's 12-month performance. This puts MRNA stock in the top 5% of all stocks in terms of key growth measures.
Representatives of Moderna didn't immediately return a request for comment from Investor's Business Daily.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
https://www.investors.com/news/technology/mrna-stock-rockets-biotech-doses-first-patient-coronavirus-vaccine-test/?src=A00220&yptr=yahoo